

Drug Discovery for Schizophrenia

RSC Drug Discovery Series

Editor-in-Chief:

Professor David Thurston, *King's College, London, UK*

Series Editors:

Professor David Rotella, *Montclair State University, USA*

Professor Ana Martinez, *Centro de Investigaciones Biologicas-CSIC, Madrid, Spain*

Dr David Fox, *Vulpine Science and Learning, UK*

Advisor to the Board:

Professor Robin Ganellin, *University College London, UK*

Titles in the Series:

- 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups
- 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1
- 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2
- 4: Accounts in Drug Discovery
- 5: New Frontiers in Chemical Biology
- 6: Animal Models for Neurodegenerative Disease
- 7: Neurodegeneration
- 8: G Protein-Coupled Receptors
- 9: Pharmaceutical Process Development
- 10: Extracellular and Intracellular Signaling
- 11: New Synthetic Technologies in Medicinal Chemistry
- 12: New Horizons in Predictive Toxicology
- 13: Drug Design Strategies: Quantitative Approaches
- 14: Neglected Diseases and Drug Discovery
- 15: Biomedical Imaging
- 16: Pharmaceutical Salts and Cocrystals
- 17: Polyamine Drug Discovery
- 18: Proteinases as Drug Targets
- 19: Kinase Drug Discovery
- 20: Drug Design Strategies: Computational Techniques and Applications
- 21: Designing Multi-Target Drugs
- 22: Nanostructured Biomaterials for Overcoming Biological Barriers
- 23: Physico-Chemical and Computational Approaches to Drug Discovery
- 24: Biomarkers for Traumatic Brain Injury
- 25: Drug Discovery from Natural Products
- 26: Anti-Inflammatory Drug Discovery
- 27: New Therapeutic Strategies for Type 2 Diabetes: Small Molecules
- 28: Drug Discovery for Psychiatric Disorders
- 29: Organic Chemistry of Drug Degradation
- 30: Computational Approaches to Nuclear Receptors
- 31: Traditional Chinese Medicine
- 32: Successful Strategies for the Discovery of Antiviral Drugs

- 33: Comprehensive Biomarker Discovery and Validation for Clinical Application
- 34: Emerging Drugs and Targets for Parkinson's Disease
- 35: Pain Therapeutics; Current and Future Treatment Paradigms
- 36: Biotherapeutics: Recent Developments using Chemical and Molecular Biology
- 37: Inhibitors of Molecular Chaperones as Therapeutic Agents
- 38: Orphan Drugs and Rare Diseases
- 39: Ion Channel Drug Discovery
- 40: Macrocycles in Drug Discovery
- 41: Human-based Systems for Translational Research
- 42: Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics
- 43: Carbohydrates in Drug Design and Discovery
- 44: Drug Discovery for Schizophrenia

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK
Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247,
Email: booksales@rsc.org
Visit our website at www.rsc.org/books

Drug Discovery for Schizophrenia

Edited by

Tatiana V. Lipina

Institute of Physiology, Novosibirsk, Russia

Email: lipina@physiol.ru

John C. Roder

Lunenfeld-Tanenbaum Research Institute, Toronto, Canada

Email: roder@lunenfeld.ca



RSC Drug Discovery Series No. 44

Print ISBN: 978-1-78262-026-6

PDF eISBN: 978-1-78262-249-9

ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2015

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

The RSC is not responsible for individual opinions expressed in this work.

The authors have sought to locate owners of all reproduced material not in their own possession and trust that no copyrights have been inadvertently infringed.

Published by The Royal Society of Chemistry,
Thomas Graham House, Science Park, Milton Road,
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our web site at www.rsc.org

Preface

We wish to thank our friends, family members, and colleagues who encouraged us to create this book, “Drug Discovery for Schizophrenia”. We have carefully included some of the most important directions in the field of schizophrenia, and are thankful to all contributors, who generously dedicated their time to create their chapters.

This book was motivated by our desire – and that of all the contributors – to further understand the mechanisms of schizophrenia and envision future research on this mental disorder at multiple levels; from epigenetics, genetics, neurochemistry, neuroimmunology, and animal models to opto-/chemo-genetics or protein–protein interactions. Personally, the main motivation was the wish to help Dr John Roder’s son, Nathan, who suffers from this mental disorder and who was diagnosed in his final year of secondary school.

Hopefully, our scientific attempts will ultimately lead to effective treatments for this complex brain disorder. We believe that consistent analyses of new findings in the field of schizophrenia will benefit psychiatric neuroscience to unlock this complex brain puzzle.

Tatiana V. Lipina and John C. Roder

Contents

Chapter 1	The Genetics of Schizophrenia	1
	<i>James N. Samson and Albert H. C. Wong</i>	
1.1	Introduction	1
1.2	What Genetics Can Tell Us about Schizophrenia	2
1.2.1	The Heritability of Schizophrenia	2
1.2.2	The Genetic Architecture of Schizophrenia	3
1.3	The Tools of Genomics	5
1.4	What Genetics Has Told Us about Schizophrenia	7
1.4.1	Common Variation	8
1.4.2	Rare Variation	12
1.4.3	The Future of GWASs	15
1.5	What Genetics is Telling Us about Schizophrenia	16
1.6	The Limitations of Genetic Studies of Schizophrenia	17
1.7	Conclusion	18
1.8	Definitions	19
	References	19
Chapter 2	The Impact of Epigenetics in Schizophrenia Research	28
	<i>Peter J. Gebicke-Haerter</i>	
2.1	Introduction	28
2.2	Genetic Epidemiology: The Hunt for Genes Associated with Mental Disorders	29
2.3	Where is the missing heritability?	31
2.4	Epigenetics: A New Memory System in Neurobiology	33
2.4.1	DNA Methylation	34
2.4.2	Histone Methylation	35
2.4.3	Histone Acetylation	37

2.4.4 Epigenetics of GABA-ergic Neurons and Neocortical Development	39
2.5 Conclusions	40
References	41
Chapter 3 Developmental Neuroimmune Mechanisms in Schizophrenia	46
<i>Ulrike Stadlbauer and Urs Meyer</i>	
3.1 Introduction	46
3.2 Epidemiological and Translational Studies of Prenatal Infection and Schizophrenia	47
3.3 The Role of Inflammation in Mediating the Effects of Maternal Infection in the Offspring	49
3.3.1 The Main Components of the Inflammatory Response System	49
3.3.2 Neurodevelopmental Effects of Cytokines	52
3.3.3 Epidemiological Evidence for the Role of Inflammation in Mediating the Effects of Maternal Infection on the Offspring	53
3.3.4 Experimental Evidence for the Role of Inflammation in Mediating the Effects of Maternal Infection on the Offspring	53
3.4 Fetal Brain Development in the Event of Inflammation	55
3.5 Priming of Long-term Neuroinflammation by Prenatal Infection and Inflammation	56
3.6 (Latent) Neuroinflammation and Disease Progression	57
3.7 Developmental Neuroinflammation as a Possible Target for Disease Prevention	59
3.8 Conclusions	60
References	60
Chapter 4 The Self-medication Hypothesis in Schizophrenia: What Have We Learned from Animal Models?	70
<i>Bernard Le Foll, Enoch Ng, José M. Trigo, and Patricia Di Ciano</i>	
4.1 Substance Use and Schizophrenia: Clinical Aspects	70
4.1.1 Epidemiology and Clinical Aspects	70
4.1.2 Human Studies Exploring the Impact of Nicotine on Cognition in Schizophrenia	72
4.1.3 Human Studies Exploring the Impact of Cannabis on Cognition in Schizophrenia	73
4.2 Human Studies that Explore the Impact of Smoke on the Side-effects of Antipsychotic Medications	74
4.3 Animal Models to Study the Self-medication Hypothesis	75
4.3.1 Modelling Schizophrenia in Animals	75

4.4	Testing the Predictions of the Self-medication Hypothesis	78
4.5	Review of Studies Evaluating the Impact of Nicotine on Animal Models of Schizophrenia	79
4.5.1	Animal Models of Dopamine Hyperactivity	79
4.5.2	Neurodevelopmental Models of Schizophrenia	79
4.5.3	The PPI Model of Schizophrenia	80
4.6	Review of Studies Evaluating the Impact of Cannabinoid Agonists on Animal Models of Schizophrenia	81
4.6.1	Cognitive Models	81
4.6.2	Neurodevelopmental Models	82
4.6.3	Impact on Neuroleptic Side-effects	82
4.7	Conclusions	82
	References	83

Chapter 5 Modelling Schizophrenia: Strategies for Identifying Improved Platforms for Drug Discovery **89**

John L. Waddington and Colm M. P. O'Tuathaigh

5.1	Introduction	89
5.2	Genetic Architecture of Schizophrenia	90
5.3	Behavioural Models of Schizophrenia	91
5.4	Developing Valid Experimental Models of Schizophrenia	93
5.5	Phenotypic Characterisation of Mutant Models of Schizophrenia: Additional Considerations	94
5.5.1	Sex-Specific Phenotypes and Relevance to Schizophrenia	94
5.5.2	Incorporating Developmental Clinical Trajectory into the Phenotyping Strategy	95
5.5.3	Importance of Mechanistic Interrogation of Phenotypic Effects	95
5.6	NRG1	96
5.6.1	NRG1- and ErbB-Deficient Mutant Mouse Models	96
5.6.2	Mutant Mouse Models of NRG1 and ErbB Over-Expression	98
5.6.3	NRG1–ErbB Signalling and Antipsychotic Drug Discovery	100
5.7	DISC1	101
5.8	Dysbindin	102
5.9	Modelling Gene × Environment Interactions in Schizophrenia Mutant Models	103
5.10	Modelling Gene × Gene Interactions in Schizophrenia Mutant Models	104
5.11	Conclusions	105
	Acknowledgements	106
	References	106

Chapter 6	Drugs that Target the Glutamate Synapse: Implications for the Glutamate Hypothesis of Schizophrenia	115
	<i>Catharine A. Mielnik and Amy J. Ramsey</i>	
6.1	The Glutamate Hypothesis of Schizophrenia	115
6.1.1	Molecular and Cellular Components of the Glutamate Synapse	116
6.1.2	Evidence for a State of NMDA Receptor Hypofunction	116
6.2	The Integration of Glutamate, Dopamine and GABA in Schizophrenia	119
6.2.1	Dopamine and Glutamate	119
6.2.2	GABA and Glutamate	121
6.3	Animal Models of Schizophrenia	122
6.3.1	Preclinical Drug Testing in Animal Models	122
6.3.2	CNTRICS-Based Behavioural Paradigms	123
6.4	Pharmacological Targets to Improve Glutamatergic Signaling	127
6.4.1	NMDA Receptor	127
6.4.2	Glycine and Serine	127
6.4.3	AMPA Receptor	130
6.4.4	Metabotropic Glutamate Receptors	131
	References	133
Chapter 7	Disrupted-in-Schizophrenia-1 (DISC1) Interactome and Schizophrenia	141
	<i>Tatiana V. Lipina and John C. Roder</i>	
7.1	Introduction	141
7.2	Functions of DISC1 Interactome in the Brain	142
7.2.1	Neurodevelopment	142
7.2.2	Neuronal Signalling and Synaptic Plasticity	146
7.2.3	Subcellular Functions	148
7.3	The DISC1 Interactome and Schizophrenia	150
7.3.1	Genetics	150
7.3.2	Neuroanatomical and Neurocognitive Phenotypes	151
7.4	DISC1 Interactome and Mouse Models of Schizophrenia	151
7.4.1	DISC1 Mouse Models	153
7.4.2	Mouse Models with Modified DISC1 Interactors	157
7.5	Future Directions	162
	References	164

Chapter 8	GSK3 Networks in Schizophrenia	173
	<i>Jivan Khlgatyan, Gohar Fakhfouri, and Jean-Martin Beaulieu</i>	
8.1	Introduction	173
8.1.1	GSK3-Regulating Pathways	174
8.2	GSK3 in Schizophrenia	179
8.2.1	Biological Evidence for the AKT-GSK3 Pathway in Schizophrenia	179
8.2.2	AKT-GSK3 and the Pathophysiology of Schizophrenia	181
8.2.3	Wnt-GSK3 Pathway in Schizophrenia	182
8.2.4	NRG1-GSK3 and BDNF-GSK3 in Schizophrenia	182
8.2.5	DISC1-GSK3 in Schizophrenia	184
8.3	GSK3 and Antipsychotics	185
8.4	How GSK3 Affects Behavior	186
8.4.1	Circadian Rhythms	186
8.4.2	β -Catenin	187
8.4.3	Microtubules	187
8.4.4	AMPA and NMDA Receptors	188
8.4.5	Dynamin I	188
8.5	Biomarkers	188
8.5.1	Peripheral Blood Cells and Olfactory Epithelium	189
8.5.2	MRI	189
8.5.3	Electroretinography	189
8.6	Future Prospects	190
	References	191
Chapter 9	Protein Interactions with Dopamine Receptors as Potential New Drug Targets for Treating Schizophrenia	202
	<i>Ping Su, Albert H. C. Wong, and Fang Liu</i>	
9.1	Introduction	202
9.2	Dopamine Receptors	204
9.2.1	D1-Like Dopamine Receptor Interacting Proteins	204
9.2.2	D2-Like Receptor-Interacting Proteins	217
9.3	Targeting Dopamine Receptor Interactions for Drug Development of Schizophrenia	226
	References	227

Chapter 10	Optogenetic and Chemogenetic Tools for Drug Discovery in Schizophrenia	234
	<i>Dennis Kätzel and Dimitri M. Kullmann</i>	
10.1	Introduction	234
10.2	Genetically Targeted Manipulation of Neural Activity	235
10.2.1	Optogenetic Activation	237
10.2.2	Chemogenetic Activation	239
10.2.3	Optogenetic Inhibition	239
10.2.4	Chemogenetic Inhibition	240
10.2.5	Silencing of Synaptic Transmission	241
10.2.6	Ablation of Cells	241
10.2.7	Optochemical Genetics and Optical Pharmacology	241
10.2.8	Optogenetic Interference with Subcellular Signalling	242
10.2.9	Chemogenetic Interference with Subcellular Signalling	243
10.3	Getting Started: How to Bring Optogenetics and Chemogenetics to the Laboratory	243
10.3.1	General Considerations: Which Molecular Tools?	243
10.3.2	Implementation in the Laboratory	248
10.4	Application of Optogenetics and Chemogenetics in Neurological and Psychiatric Diseases	251
10.4.1	Principal Applications: The Road to Drug Discovery	251
10.4.2	Optogenetic and Chemogenetic Investigation of Neurological Diseases	253
10.4.3	Optogenetics and Chemogenetics in Psychiatric Diseases	254
10.4.4	Optogenetic and Chemogenetic Pharmacology	261
10.4.5	An Optogenetic View on Brain and Behaviour?	262
10.5	Conclusion	264
	Acknowledgements	264
	References	264
	Subject Index	273

CHAPTER 1

The Genetics of Schizophrenia

JAMES N. SAMSON^a AND ALBERT H. C. WONG^{*a,b}

^aCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; ^bDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada

*E-mail: albert.wong@utoronto.ca

1.1 Introduction

If you know the enemy and know yourself, you need not fear the result of a hundred battles. If you know yourself but not the enemy, for every victory gained you will also suffer a defeat. If you know neither the enemy nor yourself, you will succumb in every battle.

Sun Tzu, *The Art of War*

The greatest difficulty in finding treatments for schizophrenia is that we do not know the enemy well enough. Revealing the complex etiology and pathophysiology of schizophrenia has posed a considerable challenge for researchers, but improving technology is now enhancing our ability to use the wellspring of information present in the genome to help find these answers. It is more than three decades since the first development of genome sequencing technology,¹ and we have come to appreciate the intricate way in which variations in the genome can influence disease. Genetic research has provided insights into elucidating the pathophysiology of many diseases,^{2,3} and also promises to improve clinical outcomes through personalized treatments and targeted therapeutics.⁴⁻⁶ Studying the genetics of schizophrenia is important

to discover genes and pathways that contribute to its development. The hope is that the symptoms of schizophrenia can be prevented or resolved by targeting therapeutics at these pathways. Still, treatment is most likely to be administered late in the development of the disorder, after diagnosable symptoms have already presented. By this time, the processes leading to the development of schizophrenia may have caused permanent changes; for example, alterations in brain morphology. Genetics can also help us to understand the underlying pathophysiology of the individual symptoms of schizophrenia, allowing for the development of targeted therapeutics to improve the lives of patients by treating symptoms after developmental pathways have become fixed. Whether to understand developmental processes or symptom pathophysiology, the study of the genetics of schizophrenia has great potential in helping us to understand the enemy, and hopefully, eventually, to conquer schizophrenia.

1.2 What Genetics Can Tell Us about Schizophrenia

It is now understood that genes and environment work together to influence the development of disease. The power of genetics to enable us to understand a disease is dependent upon how much of the variance in liability is contributed by genes compared to other factors. It is also important to consider the manner in which genes affect phenotype. The heritability and genetic architecture of schizophrenia tell us how genetic information can be used to understand the disorder.

1.2.1 The Heritability of Schizophrenia

The contribution of genes in determining a given phenotype can be quantified by estimating heritability. Heritability is a mathematical expression of the amount of variance in phenotype that is explained by genetic variation. This does not measure how much phenotypic variation is *caused* by genes; rather, it reflects the relative contribution of genetic *vs.* non-genetic factors in determining phenotype. Heritability is estimated by comparing the liability of developing a trait (schizophrenia, for example) between related and unrelated individuals.^{7,8} Twin studies have been invaluable for estimating heritability, as it is easier to differentiate between genetics and shared *vs.* differential environment in such studies.⁹ The concordance in phenotype between monozygotic (MZ) and dizygotic (DZ) twins gives a measure of the correlation between genotypic variation and presence of a trait. MZ concordance rates for schizophrenia have been reported between 41% and 65%, with DZ concordance ranging from 0% to 28%.^{10,11} Since DZ twins have approximately half the genetic variance of unrelated individuals, and MZ twins have identical genomes, heritability can be crudely calculated as twice the difference in concordance (r) between MZ and DZ twins (see eqn 1.1).⁸

$$\text{Heritability}(h^2) = 2(r(MZ) - r(DZ)) \quad (1.1)$$